# Kenan Turnacioglu

> Kenan Turnacioglu is a Series A investor at Catalio Capital Management backing Artificial Intelligence. See 6 investments, check sizes, portfolio. Updated…

- Type: Angel Investor
- Fund: [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management)
- Location: New York, United States
- Total investments: 6
- Last investment: Feb 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/turnacioglu/

Kenan Turnacioglu is a General Partner & Member of the Investment Committee at Catalio Capital Management.He is also the Chairman of PaigeAI, a machine learning pathology company spun out of Memorial Sloan Kettering. In 2011, Kenan co-founded PointState Capital, LP and managed the portfolios and investment teams in Healthcare and Consumersectors, before departing in 2018. From 2001 to 2010, he worked at Duquesne Capital Management, LLC managing Healthcare investments. While at these positions he also served on the Boards of StemCentrx (2013-2016), Agensys (2004-2007), and NYU Langone Cancer Center (2010-2015). From 1998-2000, he worked at Credit Suisse as an analyst on the biotech team.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 4 | 67% |
| Medical | 2 | 33% |
| Software | 2 | 33% |
| Biopharma | 2 | 33% |
| Health Care | 2 | 33% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series B | 2 | 33% |
| Seed | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Network Bio | Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $17M | Seed | Feb 27, 2025 |  |
| Massive Bio | Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncologysub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time. | $16.5M | Series A | Jun 02, 2022 |  |
| Massive Bio | Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncologysub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time. | $16.5M | Series B | Jun 02, 2022 |  |
| Immunai | Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample,and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.The company is located in New York City, San Francisco, and Tel Aviv, Israel. | $60M | Series A | Feb 11, 2021 |  |
| Sirona Medical | Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care. | $9M | Series A | Aug 28, 2020 |  |
| Paige | Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology,Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products. | $45M | Series B | Dec 18, 2019 |  |

6 of 6 investments shown.

## Co-investors
- [Breyer Capital](https://shizune.co/investors/profile/breyer-capital) — VC Fund, 2 deals together
- [KFW DEG](https://shizune.co/investors/profile/kfw-deg) — VC Fund, 2 deals together
- [Revo Capital](https://shizune.co/investors/profile/revo-capital) — VC Fund, 2 deals together
- [Charles and Lynn Schusterman Family Philanthropies](https://shizune.co/investors/profile/schusterman-family-philanthropies) — VC Fund, 2 deals together
- [Charles and Lynn Schusterman Family Philanthropies](https://shizune.co/investors/profile/schusterman-foundation) — VC Fund, 2 deals together
- [THE CATALYTIC IMPACT FOUNDATION (CIF)](https://shizune.co/investors/profile/the-catalytic-impact-foundation-cif) — VC Fund, 2 deals together

## About Catalio Capital Management

VC Fund · Baltimore, United States

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.

5 contacts available at Catalio Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Ben Snedeker | Partner and Co-Head Public Equities | https://shizune.co/investors/profile/ben-snedeker |
| George Petrocheilos | Co-Founder & Managing Partner | https://shizune.co/investors/profile/george-petrocheilos |
| Isaac Ro | Partner | https://shizune.co/investors/profile/isaac-ro |
| Jacob Vogelstein | Co-Founder and Managing Partner | https://shizune.co/investors/profile/jacob-vogelstein |
| Kenan Turnacioglu | General Partner | https://shizune.co/investors/profile/kenan-turnacioglu |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kenan Turnacioglu invest in?

Kenan Turnacioglu invests primarily in Artificial Intelligence, Medical and Software startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kenan Turnacioglu last invest?

The most recent investment recorded for Kenan Turnacioglu closed in Feb 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co